In this study, YXF can upregulate miR133a, inhibit the myocardial TGF‐β/Smads pathway, improve blood glucose levels and myocardial fibrosis, and thus have the potential to treat DCM. The gene discussed is TGFB1; the disease is familial dilated cardiomyopathy.